Esben Matzen Bech

Esben Matzen Bech is a notable inventor based in Høsholm, Denmark. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that target amylin receptors. His work is crucial in addressing medical conditions such as obesity, NASH, and diabetes.

Latest Patents

Esben Matzen Bech holds a patent for "HAManalogues with improved amylin receptor (hAMY3R) potency." This invention relates to hAManalogues that exhibit enhanced potency for the amylin receptor, specifically hAMY3R, with an effective concentration (EC) of ≤250 pM. The invention is based on the sequence of the human adrenomedullin fragment hAM and includes selective amylin receptor agonists that maintain good physical stability. The patent outlines the potential use of these polypeptides in pharmaceutical compositions for treating various medical conditions.

Career Highlights

Esben Matzen Bech is associated with Gubra A/S, a company focused on innovative solutions in the field of metabolic diseases. His work at Gubra has positioned him as a key player in the development of new therapeutic approaches.

Collaborations

Esben has collaborated with notable colleagues, including Jens Christian Frøslev Nielsen and Kristoffer Tobias Gustav Rigbolt. These collaborations have further enhanced the research and development efforts within the company.

Conclusion

Esben Matzen Bech's contributions to amylin receptor research and his innovative patent highlight his role as a significant inventor in the pharmaceutical industry. His work continues to pave the way for advancements in treating metabolic disorders.

Profile summary based on public USPTO records.